SENS
NASDAQSenseonics Holdings
$7.02
+1.87 (+36.31%)
2026-08-07 00:00
Healthcare
Medical Devices
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$262.6M
P/E Ratio
N/A
52W Low
52W High
$0.41
$8.75
Volume
2.2M
Analyst Rating
Hold
Target: $17
10 Analyst Ratings
Strong Buy
0
Buy
0
Hold
10
Sell
0
Price Target Range
Low: $13
Avg: $17
High: $19
About Senseonics Holdings
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time d...
Employees
130
Website
senseonics.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | $35.3M | -193.8% | -$69.1M | -$58.0M |
| 2024 | $22.5M | -333.0% | -$78.6M | -$58.2M |
| 2023 | $22.4M | -337.7% | -$60.4M | -$69.8M |
| 2022 | $16.4M | -418.7% | $142.1M | -$66.0M |
| 2021 | $13.7M | -418.1% | -$302.5M | -$55.9M |
| 2026 Q1 | $11.7M | -271.9% | -$32.3M | -$31.9M |
| 2025 Q4 | $14.3M | -146.8% | -$20.8M | -$17.6M |
| 2025 Q3 | $8.1M | -242.1% | -$19.5M | -$15.7M |
| 2025 Q2 | $6.6M | -215.4% | -$14.5M | -$9.1M |
| 2025 Q1 | $6.3M | -215.6% | -$14.3M | -$15.6M |
| 2024 Q4 | $8.3M | -172.0% | -$15.5M | -$14.2M |
| 2024 Q3 | $4.3M | -535.9% | -$24.0M | -$14.6M |
| 2024 Q2 | $4.9M | -400.7% | -$20.3M | -$9.1M |